DALLAS, Sept. 15, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com) — The Chief Executive Officer of NeOnc Technologies Holdings (NASDAQ:NTHI), Amir F. Heshmatpour has purchased another 37,000 shares of the company’s common stock, adding to his investment following NeOnc’s announcement of a $15 million financing with healthcare-focused institutional investors.
A September 14 Form 4 shows that Heshmatpour acquired shares on September 11 at a weighted-average price of $3.6654 per share, representing approximately $135,620 of additional investment. The transaction continues his previously disclosed pattern of purchasing NeOnc shares.
The institutional financing, announced September 9, was priced at $4.20 per common share and accompanying warrant, with pre-funded warrants available in place of common shares. The offering covers approximately 3.57 million shares or equivalents, plus warrants to purchase another 3.57 million shares at an exercise price of $4.20 over a five-year term. The company identified working capital, general corporate purposes and redemption of Series A convertible preferred stock as intended uses of the net proceeds.
The combination of continued insider buying and institutional backing is tyipically an expression of investor determination, in this case in support of NeOnc’s effort to beat brain cancer. Heshmatpour is increasing his personal financial commitment as the company works to advance novel therapies built on its patented NEO technology platform.
That platform addresses a central challenge in treating brain tumors: delivering therapeutic agents to the brain. NeOnc has exclusively licensed a worldwide portfolio of issued patents and pending applications from the University of Southern California covering NEO100, NEO212 and related technologies. The company reports patent protections extending up to 2038.
NEO100 is a patented formulation of highly purified perillyl alcohol administered through the nose and designed to reach the brain along olfactory and trigeminal pathways. Patients in its Phase 2a study self-administered the investigational treatment at home.
On August 12, NeOnc reported positive topline results from that study in 24 patients with recurrent or progressive high-grade IDH1-mutant glioma. In the company’s reported analysis, six-month progression-free survival was 48.9%, compared with a prespecified 20% historical benchmark, and median overall survival was 26.09 months.
Behind those results are patients and families hoping for more time together. At the August 12 readout, NeOnc reported that one patient had remained progression-free for approximately 19 months and five of the 24 participants were still receiving treatment.
At-home dosing also raises an important quality-of-life possibility. Taking daily doses in familiar surroundings could reduce travel for treatment administration and ease some of the “white coat” anxiety associated with medical settings. For patients and caregivers, that may mean a less disruptive routine and more time around family, while maintaining necessary clinical follow-up. These are potential benefits of the delivery approach; NeOnc said quality-of-life analyses were still underway at the August 12 readout.
Following the readout, NeOnc said it intended to request a Type B meeting with the FDA to discuss a potential registrational development path. “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study,” Heshmatpour said in the company’s August 12 announcement.
NeOnc’s second lead candidate, NEO212, links perillyl alcohol with temozolomide in an oral molecule designed to improve delivery across the blood-brain barrier. In its June 16 update, the company reported completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose, providing another clinical program through which to evaluate the platform.
Both therapies remain investigational. The NEO100 results came from a small, single-arm, open-label study without a randomized control group, and further clinical evidence and regulatory review will be needed to establish whether the treatment can reach patients through an approved indication.
The pattern of progress is coming into focus; NeOnc’s reported clinical results, its CEO’s continued share purchases, and recent institutional backing are beginning to tell a consistent story. That alignment brings together important ingredients for potential success as the company works toward its next clinical and regulatory milestones.
About InvestorsTape.com
At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.
Contact
benh@investorstape.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.
General Disclaimer
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.
This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities.
This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.
